BIOG-B

BioGaia is a Swedish probiotics company that develops, manufactures, markets, and sells probiotic products for gut, immune, and oral health. Founded in 1990, the company focuses on Limosilactobacillus reuteri (L. reuteri) bacterial strains, including the patented L. reuteri Protectis and L. reuteri BG-R46. Its product portfolio includes infant oil drops, tablets, and the Prodentis brand for oral health. BioGaia operates in the EMEA, Americas, and APAC regions, selling through distribution partners and direct subsidiaries. The group includes subsidiaries such as BioGaia USA, BioGaia Canada, BioGaia Germany & Austria, BioGaia France, BioGaia UK, BioGaia Japan, BioGaia Australia & New Zealand, BioGaia Finland, BioGaia Pharma, BioGaia New Sciences, BioGaia Invest, and BioGaia Production. The company collaborates with academic researchers worldwide and maintains a dedicated research and development team.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Biotechnology Homepage biogaiagroup.com
Sector Healthcare IR page biogaiagroup.com
Tags
probiotics, gut health, immune health, oral health, microbiome research, infant nutrition, l. reuteri, functional food, dietary supplements, Limosilactobacillus reuteri, L. reuteri Protectis, L. reuteri BG-R46, Reuteri, BRA-mjölk, BRA Milk, LifeTop, LifeTop Straw, LifeTop Cap, Prodentis, Prodentis FRESH BREATH, BioGaia USA, BioGaia Canada, BioGaia Germany & Austria, BioGaia France, BioGaia UK, BioGaia Japan, BioGaia Australia & New Zealand, BioGaia Finland, BioGaia Pharma, BioGaia New Sciences, BioGaia Invest, BioGaia Production
Press page biogaiagroup.com/sv/pressrum

Metrics

Valuation  
Market cap kr 9.905B
Market cap (USD) $ 974.964M
P/E 28.55
PEG —
P/BV 9.00
P/S 6.44
P/OCF 32.31
P/FCF —
Dividend yield 7.0%
Turnover / mcap —
Returns  
ROE 21.9%
ROI 25.3%
ROIC 24.8%
Profit margin 21.6%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -3.8%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 15
Quality score 33.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007
Revenue 1.538B 1.423B 1.297B 1.104B 785.11M 747.07M 768.347M 741.87M 615.003M 534.696M 483.241M — — — — — — — —
Net profit 332.764M 351.388M 365.352M 373.773M 196.273M 179.73M 187.347M 214.89M 180.564M 159.349M 137.497M — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007
Share price 97.91 107.9 101 317.5 518 — — — — — — — — — — — — — —
Price performance 12m -0.09 0.07 -0.68 -0.39 — — — — — — — — — — — — — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (SEK) — 98.5M 119M 131M 106M 190M 216M
↳ YoY growth +20.4% +10.2% -19.0% +79.2% +13.9%
↳ 5y CAGR +17.0%
Other receivables (SEK) — 41.5M 36.3M 18.7M 33.3M 32.3M 19.7M
Cash and deposits (SEK) 214M 1.47B 1.48B 1.49B 1.54B 1.22B 801M
Intangible assets (SEK) — 50.3M 48.1M 46.1M 46.2M 767,000 702,000
Right-of-use assets (SEK) — 28.9M 15.1M 13.6M 36.2M 30.2M 22.9M
Cash flow detail
Operating cash flow (SEK) — 221M 222M 319M 426M — —
Purchases of property, plant and equipment (SEK) — -16.1M -6.38M -17.9M -48.6M -13.8M -3.52M
Purchases of intangible assets (SEK) — — — -225,000 -146,000 -397,000 -75,000
Change in receivables (cash effect) (SEK) — 47M -18M -12.4M 3.75M -85.6M -40.1M
Change in inventories (cash effect) (SEK) — -2.35M 9.82M -34.1M -40.9M 31.8M -24.9M
Change in payables (cash effect) (SEK) — 4.33M 6M 41.9M 36M 4.16M 22.1M
Dividends paid (cash effect) (SEK) — -65M -68.9M -301M -293M -697M -698M
Interest paid (cash effect) (SEK) — -803,000 -1.13M -5.39M -789,000 -1.45M -780,000
Income taxes paid (cash effect) (SEK) — -72.1M -55.9M -54.9M -80.3M 112M 113M
Operating cash flow before change in receivables (SEK) — 174M 240M 331M 422M — —
Free cash flow (OCF - PPE - intangibles) (SEK) — 205M 215M 301M 377M — —
Income detail
Research and development expense (SEK) — 105M 105M 107M 107M 157M 116M
↳ 5y CAGR +2.0%
Total comprehensive income (SEK) — 176M 198M 399M 356M 374M 291M
Comprehensive income to owners (SEK) — 176M 198M 399M 356M 374M 291M
Reported — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

NewsOctober 22, 2026

THIRD QUARTER 2026

Net sales amounted to SEK 400.4 million (326.6), an increase of SEK 73.8 million, an increase excluding currency effects of 23% (23% including currency effects).

Net sales in the Pediatrics segment amounted to SEK 293.3 million (242.6), an increase excluding currency effects of 21% (21% including currency effects).

Net sales in the Adult Health segment amounted to SEK 104.7 million (81.6), an increase excluding currency effects of 29% (28% including currency effects).

Operating expenses amounted to SEK 159.4 million (156.5), an increase of SEK 2.8 million (2%).

Operating profit increased by 54% to SEK 132.6 million (86.0), which corresponds to an operating margin of 33% (26%).

Profit after tax amounted to SEK 110.2 million (65.9), an increase of 67%.

Earnings per share amounted to SEK 1.09 (0.65) before and after dilution.

Cash flow amounted to SEK 65.9 million (107.4).

Cash and cash equivalents amounted to SEK 518.3 million (728.1).
 

Key events in the third quarter of 2026

On 31 August BioGaia announced that it has signed a new long-term exclusive distribution agreement with Recordati for Spain and Portugal.

On 9 September BioGaia announced the launch of BioGaia® Colus®, a probiotic formulation designed to promote colon health through a strain-specific and targeted delivery approach. The product contains the proprietary probiotic strain L. reuteri BG-R59®.

On 16 September BioGaia announced that it will host a Capital Markets Day in London on 8 December 2026. The Capital Markets Day will be held as an in-person event in London, and the presentations will also be broadcast live.
 

JANUARY – SEPTEMBER 2026

Net sales amounted to SEK 1,213.8 million (1,097.6), an increase of SEK 116.3 million, an increase excluding currency effects of 16% (11% including currency effects).

Net sales in the Pediatrics segment amounted to SEK 897.2 million (822.6), an increase excluding currency effects of 14% (9% including currency effects).

Net sales in the Adult Health segment amounted to SEK 309.6 million (265.9), an increase excluding currency effects of 23% (16% including currency effects).

Operating expenses amounted to SEK 513.8 million (513.3), an increase of SEK 0.5 million (0%). Operating expenses, excluding items affecting comparability, decreased by 2% to SEK 502.5 million (513.3).

Operating profit increased by 26% to SEK 365.9 million (291.5), which corresponds to an operating margin of 30% (27%).

Adjusted operating profit increased by 29% to SEK 377.2 million (291.5), which corresponds to an adjusted operating margin of 31% (27%).

Profit after tax amounted to SEK 292.8 million (234.0), an increase of 25%.

Earnings per share amounted to SEK 2.89 (2.31) before and after dilution.

Cash flow amounted to SEK -294.4 million (-483.1).
 

Key events after the end of the third quarter of 2026

No key events that are not mentioned in this interim management statement took place after the end of the third quarter.

CEO’S COMMENT

Strong growth continued in the third quarter
In the third quarter, net sales amounted to SEK 400 million, an increase of 23% excluding currency effects compared with the corresponding quarter last year, with an operating margin of 33%. Year-to-date net sales amounted to SEK 1,214 million, an increase of 16% excluding currency effects and a year-to-date adjusted operating margin of 31%.

Growth was supported by strong performance across both our Pediatrics and Adult Health segments and continued positive development in several of our key markets. Increased consumer and medical marketing activities contributed to growth in the Americas, while EMEA benefited from continued growth of our direct markets and expansion of distribution.

Double-digit growth in both segments
Our Adult Health segment continued to perform strongly, with sales increasing by 29% excluding currency effects compared with the corresponding quarter last year, with particularly strong development for our BioGaia® Prodentis® product. The Pediatrics segment also delivered steady growth, increasing by 21% excluding currency effects, supported by strong sales of BioGaia® Protectis® Drops and Protectis® Chewable Tablets.

Continued strong development across our regions
In the Americas, sales increased by 23% excluding currency effects during the quarter, with the US as a key contributor to growth. In the US oral health market, years of building awareness and recommendations among dental professionals have established a strong foundation for Prodentis®. With Prodentis® Fresh Breath, we are complementing this with increased consumer marketing across digital channels, while continuing to strengthen engagement with dentists and dental hygienists.

Latin America continues to perform well, with positive momentum in Guatemala and Peru and a turnaround in Brazil, supported by increased consumer marketing. BioGaia is now the #1 Pediatric Probiotic Food Supplement Company in Latin America1.

In EMEA, sales increased by 38% excluding currency effects during the quarter. We continue to expand distribution in our direct market France, while our UK business also delivered positive sales development, supported by expanded distribution across key retailers. The region also benefited this quarter from customers requesting certain orders be moved from Q4 into this quarter.

In APAC, sales increased by 8% excluding currency effects, with China and Korea contributing more positively to the quarter than in the first half. As highlighted previously, the region continues to be affected by variations in order timing between quarters.

Expanding our offering in adult gut health
During the quarter, we announced the launch of BioGaia® Colus® for colon health, further expanding our science-based portfolio within adult gut health. Colus® is certified as FODMAP-friendly and contains our proprietary L. reuteri BG-R59® strain, supported by two independent randomized, double-blind, placebo-controlled clinical studies. It has a unique delayed-release capsule technology that is designed to deliver the probiotic further down the gastrointestinal tract into the colon.

This new product launch is another example of how we translate our scientific expertise into targeted, clinically proven solutions that respond to evolving consumer needs. Colus® will initially be introduced in the UK, followed by a phased rollout across selected markets, supporting our ambition to further strengthen BioGaia's position within adult health.

Capital Markets Day in the fourth quarter
We look forward to hosting our Capital Markets Day in London on December 8. The event will provide an opportunity to present greater detail on BioGaia's strategy and long-term ambitions.

We will provide further perspectives on our strategic progress, science and innovation pipeline, growth opportunities, go-to-market model, operational and manufacturing capabilities, and financial framework, as well as how these areas come together to support long-term value creation for our customers, partners and shareholders.

Investors and analysts are welcome to participate either in person in London or via livestream and the invitation can be found on our corporate webpage.

Our focus on growth and profitability
As we enter the final quarter of the year, we remain focused on executing our strategy and building on the strong development we have seen so far in 2026. We continue to invest in science-based innovation, to strengthen our presence across both established and developing markets, and to expand the reach of our BioGaia brand globally.

1 Source: Euromonitor International, September 2026.
 

Theresa Agnew
President and CEO, BioGaia
October 22, 2026
 

You find the complete report with tables in the attached PDF or on https://www.biogaiagroup.com/investors/reports-and-presentations/financial-reports

Teleconference:
Investors, analysts, and the media are invited to take part in a teleconference on the interim management statement to be held today, October 22, 2026, at 09:30 a.m. CEST with CEO Theresa Agnew and CFO Alexander Kotsinas. More information about the teleconference is available here: https://events.inderes.com/biogaia/q3-report-2026/dial-in

Follow us:
Subscribe to BioGaia press releases here

LinkedIn here

NewsOctober 15, 2026

BioGaia AB’s Nomination Committee for the Annual General Meeting 2027 has been appointed based on the ownership structure as of June 30, 2026.

The Nomination Committee for the Annual General Meeting 2027 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of Alexander Kahane (Chairman of the Nomination Committee), appointed by the largest shareholder Anatom Holding AG, Anders Oscarsson, appointed by Corvatsch Invest AG, Karsten Ferm, appointed by Fjärde AP-Fonden, and Caroline Sjösten, appointed by Swedbank Robur. In addition, Mauricio Graber is a member of the Nomination Committee in his capacity as Chairman of the Board.

Shareholders wishing to submit proposals to the Nomination Committee are welcome to contact the Chairman of the Nomination Committee by letter to the address:

BioGaia AB, Nomination Committee, Kungsbroplan 3A, 112 27 Stockholm.

Follow us: Subscribe to BioGaia press releases here LinkedIn here

NewsOctober 9, 2026

BioGaia's (NASDAQ: BIOG) financial report for the third quarter of 2026 will be published at approximately 8:00 AM CEST on October 22, 2026.

The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website.

CEO Theresa Agnew and CFO Alexander Kotsinas will comment on the report and take questions at a live audiocast at 9:30 AM CEST.

Join the audiocast/teleconference: Audiocast: https://events.inderes.com/biogaia/q3-report-2026 Teleconference: https://events.inderes.com/biogaia/q3-report-2026/dial-in

Follow us: Subscribe to BioGaia press releases here LinkedIn here

Prompts

BioGaia (ticker BIOG-B), listed in Sweden.

ETFs Holding BioGaia

ETF Weight in ETF Shares Market value As of
AVDS 0.05% 16,139 $ 201.344K Nov 16, 2026
DFIS 0.03% 153,970 $ 1.932M Nov 12, 2026
AVDV 0.02% 303,300 $ 3.784M Nov 16, 2026
DXIV 0.02% 3,023 $ 37.929K Nov 12, 2026
DFSI 0.01% 13,612 $ 170.789K Nov 12, 2026
AVDE 0.01% 117,969 $ 1.472M Nov 16, 2026
AVSD 0.01% 1,531 $ 19.1K Nov 16, 2026
DFIC 0.01% 97,743 $ 1.226M Nov 12, 2026
DFAX 0.00% 45,498 $ 570.861K Nov 12, 2026
DFAI 0.00% 51,355 $ 644.349K Nov 12, 2026